0 seconds of 3 minutes, 21 secondsVolume 0%
Press shift question mark to access a list of keyboard shortcuts
00:00
03:21
03:21
 
  • Algernon (AGN) has provided an update on its planned Phase 1 clinical human study of AP-188
  • Algernon is completing the intravenous formulation that will be used in the study and has retained the Centre for Human Drug Research in the Netherlands
  • The company is planning to begin the Phase 1 study in September
  • Christopher J. Moreau, CEO of Algernon Pharmaceuticals, sat down with Daniella Atkinson to discuss the update
  • Algernon is a drug re-purposing company that investigates safe, already approved drugs, and naturally occurring compounds, for new disease applications
  • Algernon Pharmaceuticals Inc. (AGN) opened trading at C$3.42 per share

Algernon (AGN) has provided an update on its planned Phase 1 clinical human study of AP-188 (“N,N-dimethyltryptamine” or “DMT”).

The company is currently working to complete the intravenous formulation that will be used in the Phase 1 DMT study and has retained the Centre for Human Drug Research and its affiliated pharmacy at the Leiden University Medical Center in the Netherlands, to complete the work.

Algernon plans to begin the Phase 1 study in September of 2022.

Christopher J. Moreau, CEO of Algernon Pharmaceuticals, sat down with Daniella Atkinson to discuss the news.

The primary focus of Algernon’s planned Phase 1 DMT study is to investigate prolonged intravenous infusion of DMT. The resulting data will help the company plan its Phase 2 acute stroke and rehabilitation studies.

N,N-Dimethyltryptamine, or DMT, is a hallucinogenic tryptamine drug that produces effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin.

Algernon Pharmaceuticals is a drug re-purposing company that investigates safe, already approved drugs, and naturally occurring compounds.

Algernon Pharmaceuticals Inc. (AGN) opened trading at C$3.42 per share.

More From The Market Online
AI generated stock image,

@ the Bell: Markets pop on copper price and geopolitical tensions

Canada’s main stock index increased on Tuesday, driven by geopolitical tensions and uncertainties surrounding tariffs, which boosted copper.
cannabis, weed

Navigating Canada’s cannabis market in the face of U.S. tariff concerns

Canada’s cannabis market has been evolving rapidly since legalization, presenting both opportunities and challenges for investors.
AI generated stock image Canadian Maple Leaf on top of stock market graph, with people on the floor looking upward

@ the Bell: TSX starts week strong

The TSX kicked off the week with a strong rally, reflecting gains seen on Wall Street as the US might adopt a moderate tariff…